Page last updated: 2024-08-16

ribavirin and Nasopharyngeal Neoplasms

ribavirin has been researched along with Nasopharyngeal Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Brait, M; Brem, H; Casaos, J; Cecia, A; Ding, AS; Ehresman, J; Gorelick, NL; Huq, S; Ishida, W; Ji, C; Kedda, JN; Morales, M; Perdomo-Pantoja, A; Peters, M; Serra, R; Sidransky, D; Skuli, N; Suk, I; Tyler, B; Xia, Y; Zhao, T	1

Other Studies

1 other study(ies) available for ribavirin and Nasopharyngeal Neoplasms

Article	Year
Repurposing the FDA-Approved Antiviral Drug Ribavirin as Targeted Therapy for Nasopharyngeal Carcinoma. Molecular cancer therapeutics, 2020, Volume: 19, Issue:9 Topics: Animals; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoradiotherapy; Drug Repositioning; Enhancer of Zeste Homolog 2 Protein; Eukaryotic Initiation Factor-4E; Gene Expression Regulation, Neoplastic; Humans; IMP Dehydrogenase; Mice; Molecular Targeted Therapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Radiation-Sensitizing Agents; Ribavirin; Snail Family Transcription Factors; Xenograft Model Antitumor Assays	2020

Article

Year

Repurposing the FDA-Approved Antiviral Drug Ribavirin as Targeted Therapy for Nasopharyngeal Carcinoma.

Molecular cancer therapeutics, 2020, Volume: 19, Issue:9

Topics: Animals; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoradiotherapy; Drug Repositioning; Enhancer of Zeste Homolog 2 Protein; Eukaryotic Initiation Factor-4E; Gene Expression Regulation, Neoplastic; Humans; IMP Dehydrogenase; Mice; Molecular Targeted Therapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Radiation-Sensitizing Agents; Ribavirin; Snail Family Transcription Factors; Xenograft Model Antitumor Assays

2020